SuperworthPrecipio profit margin PRPO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −4.5%
- Operating margin, 12 months
- −5.7%
- Net margin on a year earlier
- +4.0 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Precipio kept −4.5% of its revenue as net profit, with an operating margin of −5.7% and a gross margin of 44.1%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −1.5% | −5.0% | 44.5% |
| FY2024 | −23.1% | −22.7% | 40.8% |
| FY2023 | −38.5% | −50.1% | 39.6% |
| FY2022 | n/a | n/a | 26.7% |
| FY2021 | −96.4% | n/a | 27.0% |
| FY2020 | n/a | n/a | 18.9% |
| FY2019 | n/a | n/a | 7.0% |
| FY2018 | n/a | n/a | 7.9% |
| FY2017 | n/a | n/a | 16.9% |
| FY2016 | n/a | n/a | 12.9% |
| FY2015 | n/a | n/a | −0.6% |
| FY2014 | −56.3% | −69.8% | 37.2% |
| FY2013 | −58.0% | −57.2% | 39.0% |
| FY2012 | −26.5% | −30.2% | 47.7% |
| FY2011 | −30.6% | −9.3% | 57.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −4.5% | +4.0 pts | −5.7% | |
| Q1 FY26 | −3.6% | +11.9 pts | −6.9% | |
| Q4 FY25 | −1.5% | +21.6 pts | −5.0% | |
| Q3 FY25 | −5.5% | +11.7 pts | −9.1% | |
| Q2 FY25 | −8.5% | +14.4 pts | −12.3% | |
| Q1 FY25 | −15.5% | +15.5 pts | −15.0% | |
| Q4 FY24 | −23.1% | +15.4 pts | −22.7% | |
| Q3 FY24 | −17.2% | +51.2 pts | −27.2% | |
| Q2 FY24 | −22.9% | +75.6 pts | −33.4% | |
| Q1 FY24 | −31.0% | n/a | −42.2% | |
| Q4 FY23 | −38.5% | n/a | −50.1% | |
| Q3 FY23 | −68.4% | n/a | −68.6% |
Against its peers
Companies in Healthcare nearest Precipio's size, closest first, today.
| Company | Profit margin |
|---|---|
| PRPOPrecipio | −4.5% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Precipio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.